Robotic Dog Intervention on Emotional Well-Being and Quality of Life
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-15
SponsorKoç University
About this trial
The hematopoietic stem cell transplantation (HSCT) process imposes a substantial psychological burden, leading to impaired emotional well-being due to intensive treatment, isolation, and immunosuppression. Patients often experience social withdrawal, loneliness, and loss of control, which may result in persistent anxiety, depressive symptoms, and reduced quality of life (QoL) if unaddressed. This study aims to evaluate the effectiveness, feasibility, and acceptability of an AI-powered robotic dog in improving emotional well-being and QoL in pediatric patients undergoing HSCT.
Eligibility criteria
Qualifiers
Pediatric patients aged 8-15 years
Diagnosed with a hematological malignancy and undergoing hematopoietic stem cell transplantation
Hospitalized in a protective isolation room during the post-transplant inpatient period
Expected to remain hospitalized under isolation for approximately 30 days post-transplant
Disqualifiers
Severe cognitive impairment or neurodevelopmental conditions preventing meaningful interaction or self-report
Acute neurological conditions, delirium, or severe psychiatric crisis (e.g., acute agitation, suicidal ideation)
Requirement for intensive care, invasive ventilation, or a clinically unstable condition
Severe visual, hearing, or motor impairments that prevent interaction with the robotic dog
Trial design
Treatments tested in this trial
- AIBO
Treatment groups
28 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov